Navigation Links
Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
Date:3/16/2010

DUBLIN, March 16, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice Letter from Teva Pharmaceuticals USA, Inc. ("Teva") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1 mg, 2mg, 3 mg, and 4mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).

INTUNIV is protected by three FDA Orange Book listed patents: U.S. Patent No. 5,854,290, Use of Guanfacine in the Treatment of Behavioral Disorders; U.S. Patent No. 6,287,599 ("the '599 patent") and U.S. Patent No. 6,811,794 ("the '794 patent") both titled Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles. The three patents expire in 2015, 2020 and 2022, respectfully.

Shire is currently reviewing the details of Teva's Paragraph IV Notice Letter which was only directed to the '599 and '794 patents.

The Hatch-Waxman exclusivity period for INTUNIV runs until September 2, 2012 therefore, ANDAs for generic versions of INTUNIV cannot be approved prior to the end of that exclusivity period.


'/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Supports Rare Disease Day 2010
2. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
3. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
4. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
5. New Shire Board Member
6. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
7. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
8. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
9. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
10. Shire Initiates Two Adult ADHD Outreach Programs
11. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... August 23, 2014 Dr. ... LLC announced today that Janet B. Arrowsmith, MD, ... consultant. NDA Partners Premier Experts are top tier ... to bring extraordinary value to the company’s clients. ... solutions to help clients successfully develop their medical ...
(Date:8/22/2014)... August 23, 2014 This is ... state of the Papain industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:8/22/2014)... August 22, 2014 Today the Academy of ... United States Court of Appeals for the D.C. Circuit challenging ... published in the Federal Register on June 25, 2014. ... contrary to the text and intent of the FAA Modernization ... Congress’ specific prohibition on any new rules or regulations regarding ...
(Date:8/22/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have been ... June 30, , Six-months ended June 30, ( in ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 , ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... Accera Inc., a privately,held biotechnology company focused on ... it has appointed William,T. Poncy, M.B.A., as vice ... commercial launch of Ketasyn (AC-1202) as a medical ... Alzheimer,s disease. "Given his strong track record ...
... Assay Development, Biomarker Identification ... and ADME/Tox Applications, ... MCET), entered into a worldwide,exclusive license and technology purchase agreement ... human liver cell lines. Corning paid MultiCell a license ...
... Alliance, the leading,management consulting firm specializing in the pharmaceutical ... as one of the best,places to work in the ... Business Journal, ranking third among midsize companies. The award,was ... annual Best,Places to Work luncheon and awards ceremony on ...
Cached Biology Technology:Accera, Inc. Names William T. Poncy Vice President of Commercial Development 2Accera, Inc. Names William T. Poncy Vice President of Commercial Development 3MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3Campbell Alliance Named 'Best Place to Work' by Triangle Business Journal 2
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... Markets ( http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the ... North America 2014-2018"  report to their ... , , ,Biometrics is a technology ... individuals based on their physical or ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... 2013) The world,s leading conservation organizations have joined together ... eastern lowland gorilla ( Gorilla beringei graueri ). Found ... Democratic Republic of Congo (DRC), Grauer,s gorilla is not only ... largest primate in the world. With their entire range ...
... advance toward overcoming a major barrier to tapping the ... medicine in developing new and more effective modern drugs. ... Information and Modeling . Andreas Bender and ... modern medicine. In the world,s largest international clinical trial, ...
... World, the first international conference examining the critical link ... the University of Pennsylvania from Wednesday, March 13, through ... Penn Institute for Urban Research (Penn IUR), in partnership ... Steering Committee representing nine schools and six centers, is ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3Penn conference tackles complex relationship between urbanization and food 2
... Construction KitTM allows graphic manipulation of DNA ... has an award winning interface design that ... addition to providing sophisticated drawing capabilities for ... the "Best Plasmid Mapping Software" by the ...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
...
...
Biology Products: